Deep Brain Stimulation | AETNA Coverage Update

Summary: Aetna, a CVS Health company, modified CPB 0208 governing deep brain stimulation coverage policy, effective March 28, 2026. Here's what billing teams need to do.

Aetna updated its deep brain stimulation coverage policy under CPB 0208 in the Aetna system. This policy governs one of the more complex neurology billing areas your team manages — coverage for DBS therapy spans multiple indications, surgical procedures, and device-related codes. The effective date of March 28, 2026 means your billing and prior authorization workflows need to reflect this update now. The policy does not list specific CPT or HCPCS codes in the version captured here — we'll address what that means for your team below.

Quick-Reference Table

Aetna Deep Brain Stimulation Coverage Criteria and Medical Necessity Requirements 2026

CPB 0208 in the Aetna system governs whether deep brain stimulation qualifies as medically necessary — and Aetna applies strict criteria before it will consider coverage. The real issue here is that DBS is not a simple yes/no coverage determination. It covers a range of neurological and psychiatric indications, and each one carries its own medical necessity threshold.

The policy does not list specific CPT or HCPCS codes in the version captured for this update. That's a problem if your billing team is relying on a cached version of the policy. Pull the current CPB 0208 text directly from Aetna's Clinical Policy Bulletins before March 28, 2026 — don't build your charge capture or prior auth workflows off an older version.

What we know about Aetna's historical approach to this coverage policy is worth laying out. Aetna has generally covered DBS for essential tremor, Parkinson's disease, and dystonia when specific clinical criteria are met. These typically include documented failure of adequate medication trials, confirmation of diagnosis by a movement disorder specialist, and evaluation at a center with demonstrated DBS program experience.

For obsessive-compulsive disorder, Aetna has recognized a Humanitarian Device Exemption pathway — meaning coverage is possible but carries additional documentation requirements. The medical necessity bar for psychiatric indications is higher, and prior authorization is non-negotiable for those cases.

Epilepsy-related DBS has been an area of evolving coverage. Aetna has moved this indication from experimental toward covered status for specific refractory epilepsy populations in recent policy cycles — and this March 2026 modification may reflect further movement on that front.

The bottom line: if you're billing DBS for any indication other than Parkinson's or essential tremor, assume prior authorization requirements apply and that the medical necessity documentation standard just got reviewed.

Aetna Deep Brain Stimulation Exclusions and Non-Covered Indications

Aetna has historically classified several DBS applications as experimental, investigational, or unproven. These designations directly drive claim denial — and they shift with policy modifications.

Applications that have carried experimental status in prior versions of CPB 0208 include DBS for treatment-resistant depression outside of approved trials, Alzheimer's disease, minimally conscious states, and chronic pain indications without a specific qualifying diagnosis. Aetna has generally not covered DBS for cluster headache, Tourette syndrome outside of approved research protocols, or addiction-related indications.

This is where the modification matters most. If Aetna reclassified any indication — moving it from experimental to covered, or from covered to not covered — your prior auth denials will tell the story fast. Don't wait for the denials. Read the updated policy language before the effective date of March 28, 2026.

If you run a program that treats any of the non-traditional DBS indications above, talk to your compliance officer before submitting claims dated March 28 or later. The financial exposure on an experimental designation is significant — Aetna does not cover experimental procedures, and that determination can apply retroactively to authorizations issued before the policy changed.

Coverage Indications at a Glance

The specific code-level criteria are not available in the version of CPB 0208 captured here. The table below reflects Aetna's historical coverage framework for DBS indications. Confirm each status against the current policy text before billing.

Aetna Deep Brain Stimulation Billing Guidelines and Action Items 2026

Deep brain stimulation billing involves high-dollar claims, complex prior auth requirements, and multi-code encounters. A policy modification to CPB 0208 touches all of it.

CPT, HCPCS, and ICD-10 Codes for Deep Brain Stimulation Under CPB 0208

The version of CPB 0208 captured for this policy change does not include a published list of specific CPT, HCPCS, or ICD-10 codes. Do not use this section as your code list for billing.

Aetna's clinical policy bulletins typically include code tables as part of the full document. Access the complete CPB 0208 text at Aetna's Clinical Policy Bulletins to get the authoritative code list associated with this update.

For reference, deep brain stimulation billing generally involves a set of CPT codes covering initial implantation, pulse generator placement, electrode placement, intraoperative programming, and subsequent programming sessions — as well as replacement and revision codes. It also involves HCPCS codes for the implanted pulse generator and leads. Each of those code groups can carry different coverage rules under a policy like CPB 0208. Confirm every code against the current policy text before building or updating your charge capture.